

1 ENGROSSED SENATE
2 CONCURRENT
3 RESOLUTION NO. 37

By: Pittman, Matthews, Allen,
Anderson, Barrington, Bass,
Bice, Bingman, Boggs,
Brecheen, Brooks, Brown,
Crain, Dahm, David,
Dossett, Fields, Floyd,
Ford, Fry, Garrison,
Griffin, Halligan, Holt,
Jech, Jolley, Justice,
Loveless, Marlatt, Mazzei,
Newberry, Paddack, Quinn,
Schulz, Sharp, Shaw,
Shortey, Silk, Simpson,
Smalley, Sparks,
Standridge, Stanislawski,
Sykes, Thompson, Treat,
Wyrick and Yen of the
Senate

and

Young, Shelton and Goodwin
of the House

15 A Concurrent Resolution recognizing the importance of
16 breast cancer awareness; designating April 26, 2016,
17 as Breast Cancer Awareness Day in Oklahoma.

18
19 WHEREAS, breast cancer is the second most common cancer among
20 American women, with one in eight women being diagnosed with breast
21 cancer in her lifetime. In 2016, an estimated 246,000 new cases of
22 invasive breast cancer are expected to be diagnosed in women in the
23 U.S., along with 61,000 new cases of non-invasive (in situ) breast
24 cancer; and

1 WHEREAS, breast cancer in men is rare, but men should also be
2 educated about their risks, as they have a 1 in 1,000 chance of a
3 breast cancer diagnosis. In 2016, an estimated 2,600 men will be
4 diagnosed with breast cancer; and

5 WHEREAS, diagnosing breast cancer in women under the age of 40
6 is more difficult, because their breast tissue is generally denser
7 than in older women. By the time a lump in a younger woman's breast
8 can be identified, the cancer may be advanced. Additionally, breast
9 cancer in younger women can be aggressive and less likely to respond
10 to treatment, making it crucial that younger women discuss with
11 their doctors methods beyond standard care; and

12 WHEREAS, a triple negative breast cancer diagnosis, which is
13 more common among African American women than any other ethnic
14 group, often means that a tumor is estrogen receptor-negative,
15 progesterone receptor-negative and HER2-negative, thus giving rise
16 to the name "triple negative breast cancer." While this type of
17 breast cancer is typically responsive to chemotherapy, triple
18 negative tumors generally do not respond to receptor targeted
19 treatments. Depending on the stage of its diagnosis, triple
20 negative breast cancer can be particularly aggressive, and more
21 likely to recur than other subtypes of breast cancer; and

22 WHEREAS, currently there are more than 3 million breast cancer
23 survivors in the U.S.; and

24

